Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $237 thousand versus the consensus estimate of $270 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.